pharmaphorum3d
Intercept hit hard as NASH trial misses the mark
"Achieving statistical significance on a histology endpoint in compensated cirrhosis due to NASH has proven to be an extremely high bar in clinical trials," said Intercept's chief medical officer ...
Medscape3d
Current Management of Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) and its more severe form NASH are common liver diseases ... induced inflammation and improving cellular histology. Successful treatment will need to ...
pharmaphorum1d
Analysts tip Inventiva's lanifibranor as NASH blockbuster
Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...
Medscape2d
Intestinal Permeability – A New Target for Disease Prevention and Therapy
Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a ...
gut.bmj6d
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
gmx.net Objective Monocyte chemoattractant protein-1 (MCP-1, CCL2), the primary ligand for chemokine receptor C–C chemokine receptor 2 (CCR2), is increased in livers of patients with non-alcoholic ...